# Long-Term Follow-up Protocol

> **NCT04917887** · — · RECRUITING · sponsor: **Krystal Biotech, Inc.** · enrollment: 50 (estimated)

## Conditions studied

- Dystrophic Epidermolysis Bullosa
- Recessive Dystrophic Epidermolysis Bullosa
- Dominant Dystrophic Epidermolysis Bullosa

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT04917887
- **Lead sponsor:** Krystal Biotech, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2021-05-25
- **Primary completion:** 2028-05-25
- **Final completion:** 2028-05-25
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2021-06-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04917887

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04917887, "Long-Term Follow-up Protocol". Retrieved via AI Analytics 2026-08-12 from https://api.ai-analytics.org/clinical/NCT04917887. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*